Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.…
Why Did Zoetis Stock Move?
Zoetis (NYSE: ZTS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 14,500 employees.
The shares were at 79.11 USD on 20 November 2026, down 31.4% over 52 weeks. Its 52-week range is 68.77 USD to 132.49 USD: the price is 40.3% below the high and 15.0% above the low.
At a market capitalisation of 32.14B USD, it trades at 13.5 times trailing earnings and 12.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.1, a discount of 49% for ZTS. It pays a dividend yielding 2.62% (it pays out 35% of its earnings), against a median of 1.91% among the dividend payers in that peer group.
Zoetis reports return on equity of 80.2%, an operating margin of 37.9% and revenue down 1.3% year over year.
Its debt exceeds its cash by 7.72B USD, a debt-to-equity ratio of 2.77. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 89.69 USD is 13.4% above the current price. The next earnings report is expected on 11 February 2027.